Ardelyx Stock Up 70%: What to Know About This $490,000 Insider Transaction
This biotech specializing in gastrointestinal and cardiorenal therapies reported a notable insider sale following strong 1-year returns.
Ardelyx Stock Up 70%: What to Know About This $490,000 Insider Transaction
Overview
On June 22, 2026, Ardelyx (NASDAQ:ARDX) Chief Patient Officer Laura Williams reported the sale of 81,898 shares of Common Stock for a transaction value of approximately $490,000, according to a SEC Form 4 filing.
Transaction value based on SEC Form 4 weighted average purchase price ($5.99); post-transaction value based on June 18, 2026 market close ($6.05).
Details
* 1-year performance is calculated using June 18, 2026 as the reference date.
Source
Originally published at www.fool.com.
Related Articles
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Data may be delayed up to 15 minutes. Past performance is not indicative of future results. Consult a licensed financial advisor before making investment decisions.
